 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12345678910111213...99100» |
- Updated efficacy and safety of CDK4/6 inhibitors plus endocrine therapies in elderly HR+/HER2- metastatic or advanced breast cancer: patient-level network meta-analysis (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1815;
- BGB-43395 / BeiGene
First-in-human phase 1a, dose-escalation study of BGB-43395 (CDK4-selective inhibitor) as monotherapy and in combination with fulvestrant or letrozole in patients with metastatic HR+/HER2+ breast cancer and other advanced solid tumors (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1760;
- Genomic Profiles of Early Progressors vs Exceptional Responders on CDK4/6i in ER+ HER2- Advanced Breast Cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1750;
- Kisqali (ribociclib) / Novartis
Distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2? early breast cancer (EBC) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1733;
- Metastatic disease in patients with early breast cancer and a low Oncotype DX (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1732;
- PMD-026 / Phoenix Molecular Designs
PMD-026, a First-in-Class RSK Inhibitor, Overcomes Acquired Resistance to CDK4/6 Inhibitors or Aromatase Inhibitors in HR+/HER2- Breast Cancer Preclinical Models (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1708;
- BGB-43395 / BeiGene
Trial in progress: First-in-human phase 1a/1b, dose-escalation/expansion study of BGB-43395 (CDK4 selective inhibitor) as monotherapy or combination therapy in Chinese patients with metastatic HR+/HER2- breast cancer & other advanced solid tumors (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1707;
- Ibrance (palbociclib) / Pfizer, gedatolisib (PF-05212384) / Celcuity
Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1706;
- Ibrance (palbociclib) / Pfizer
Phase I Safety and Efficacy Study of Autophagy Inhibition to Augment the Antiproliferative and Biological Effects of Low Dose Palbociclib plus Letrozole in Estrogen Receptor-Positive, HER2-negative Metastatic Breast Cancer (MBC) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1700;
- alisertib (MLN8237) / Puma
ALISertib in combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative recurrent or metastatic breast CAncer: the phase 2 ALISCA-Breast1 study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1695;
- Comprehensive Analysis of Breast Cancer Treatment and Patient Characteristics in a Nationwide Cross-Sectional Study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1633;
- Impact of Estrogen Receptor Targeting Drugs on a Novel Epithelial-Mesenchymal Transition Pathway in Endocrine Resistant Breast Cancer: Implications for Metastasis (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1627;
- Ibrance (palbociclib) / Pfizer
Primary results and the transcriptomic analysis of PELOPS, a randomized phase II study of neoadjuvant palbociclib with or without endocrine therapy for breast cancer patients with invasive lobular carcinoma or invasive ductal carcinoma. (Stars at Night 3-4) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1462;
- Real-World Efficacy and Outcomes of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer: A Retrospective Analysis from Russia (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1402;
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
A Phase II study of dalpiciclib combined with letrozole, pertuzumab and trastuzumab as neoadjuvant therapy in HR+/HER2+ breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1386;
- Piqray (alpelisib) / Novartis
Prognostic value of circulating tumor DNA (ctDNA) dynamics and protein biomarkers in patients treated with alpelisib (ALP) and endocrine therapy (ET) for HR+/HER2 (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1202;
- letrozole / Generic mfg.
Gene expression changes following pre-operative letrozole therapy among postmenopausal women with estrogen-receptor positive HER2/neu-negative invasive breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1089;
- Validation of the association between TILs, ER status and benefit of radiotherapy in node positive, breast cancer patients: a DBCG study. (Hall 1) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1068;
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Genome-wide association study (GWAS) of aromatase inhibitor musculoskeletal toxicity (AIMT) among early-stage breast cancer (BC) survivors. (Hemisfair Ballroom 3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1042;
P=N/A
Results of this relatively large prospective cohort identified several SNPs that might be involved in AIMT. Further analyses are warranted for model validation and to better elucidate the mechanistic role of the described genetic variants from a functional perspective.
- Intrinsic Subtype at Progression to CDK4/6 Inhibitors Plus Endocrine Therapy in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer (MBC). (Hemisfair Ballroom 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_993;
- Kisqali (ribociclib) / Novartis
First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2- advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype & gene & signature expression. (Hemisfair Ballroom 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_992;
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Dalpiciclib versus placebo in combination with letrozole or anastrozole as first-line treatment for women with HR+/HER2- advanced breast cancer: prespecified final analysis of progression-free survival of the phase 3 DAWNA-2 trial. (Hemisfair Ballroom 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_987;
- goserelin acetate / Generic mfg., exemestane / Generic mfg.
A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2-Breast Cancer (EVANGELINE) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_973;
- camizestrant (AZD9833) / AstraZeneca, saruparib (AZD5305) / AstraZeneca
A randomized phase III study of first-line saruparib (AZD5305) + camizestrant vs CDK4/6i plus physician's choice endocrine therapy or + camizestrant in patients w/ BRCA1/BRCA2/PALB2 mutations & HR+/HER2- advanced breast cancer (EvoPAR-Breast01) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_912;
- Real-world Experience with CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic and Recurrent Breast Cancer in Asian Population (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_896;
- Kisqali (ribociclib) / Novartis
Impact of body mass index (BMI) on the safety and efficacy of ribociclib (RIB) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): pooled analysis of the MONALEESA (ML)-2, -3, and -7 trials (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_885;
- Efficacy of cyclin-dependent kinase 4/6 inhibitor + endocrine therapy in patients w/ hormone receptor-positive, HER2-negative advanced or metastatic breast cancer w/ liver or lung only metastases: a US Food & Drug Administration pooled analysis (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_884;
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer with Letrozole in the Advanced setting (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_865;
- Long-term administration of endocrine therapy on the gut microbiota of breast cancer patients between disease-free and recurrence (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_833;
- Venclexta (venetoclax) / Roche, AbbVie, Ibrance (palbociclib) / Pfizer
Results from PALVEN: A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL2-Positive Metastatic Breast Cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_825;
- Tissue-free minimal residual disease testing in 2, 000 consecutive patients with breast cancer: real-world data and case report (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_768;
- Molecular effects of short pre-operative endocrine therapy in hormone receptor-positive and HER2-negative early breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_766;
- Challenges and Communication Gaps in Adjuvant Endocrine Therapy for HR+ Breast Cancer Patients in Russia: Insights from an online Survey (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_763;
- Ibrance (palbociclib) / Pfizer
Correlation of cell cycle arrest and intrinsic subtype with pathologic nodal status after neoadjuvant endocrine therapy (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_708;
- Clinical Case Vignette: Estrogen Receptor Targeting PET Imaging to Monitor Treatment Response to Endocrine Therapy in Lobular Breast Cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_610;
- A case report of paraneoplastic rapidly progressive cerebellar syndrome in a patient with locally recurrent hormone receptor positive (HR+)/HER2- breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_601;
- Piqray (alpelisib) / Novartis, Truqap (capivasertib) / Otsuka, AstraZeneca
A case of sequential alpelisib and capivasertib in a patient with metastatic breast cancer harboring both a PIK3CA and AKT mutations (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_600;
- Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer and Use of Concomitant Proton Pump Inhibitors: Real-World Experience from a Tertiary Care Center (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_591;
- Periprosthetic breast implant seroma: a case report and discussion on BIA-ALCL (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_553;
- Managing Heterogeneous Metastatic Breast Cancer: A Clinical Case Vignette (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_548;
- Intrathecal therapy in invasive lobular carcinoma with non-bulky leptomeningeal disease: case report (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_545;
- Verzenio (abemaciclib) / Eli Lilly
Comparative Analysis of the Oncotype DX Breast Recurrence Score (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_507;
- Kisqali (ribociclib) / Novartis
Vitiligo-like reaction in a patient with metastatic RH+/HER2-negative breast cancer treated with ribociclib: A case report and literature review (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_496;
- Kisqali (ribociclib) / Novartis
Dissecting the tumor immune microenvironment by single cell transcriptomics and immune repertoire analysis in breast tumors treated with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib. (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_311;
- Body weight modification during adjuvant ovarian suppression for premenopausal women with luminal breast cancer. (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_291;
- Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17). (Hall 1) - Nov 1, 2024 - Abstract #SABCS2024SABCS_257;
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Vaccination with MUC-1-targeting tecemotide improves Survival of patients receiving neo-adjuvant chemotherapy for early breast cancer: Results from the Prospective Randomized ABCSG 34 Trial. (Stars at Night 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_194;
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC). (Stars at Night 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_177;
- || Verzenio (abemaciclib) / Eli Lilly
Review, Journal, Metastases: Patient with hormone receptor?positive Her2?negative metastatic breast cancer with visceral crisis with good response to abemaciclib and letrozole: A case report and review of the literature. (Pubmed Central) - Oct 31, 2024
Furthermore, the side effects were manageable and no dose reductions were necessary during treatment. These findings suggest that the combination of CDK4/6i and ET in the treatment of HR+/HER2-advanced breast cancer cannot be underestimated.
- | Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Oct 30, 2024
P2, N=47, Active, not recruiting, Sponsor: City of Hope Medical Center
These findings suggest that the combination of CDK4/6i and ET in the treatment of HR+/HER2-advanced breast cancer cannot be underestimated. Recruiting --> Active, not recruiting